Stryker (SYK) is back in the spotlight after using the American Academy of Orthopaedic Surgeons 2026 meeting in New Orleans to roll out new 3D printed knee components and expanded Mako SmartRobotics offerings.

The latest product launches land after a run where the share price has a 30 day share price return of 4.7% and an 11.2% share price return year to date. The 5 year total shareholder return of 72.7% points to strong longer term compounding.

If this kind of medical technology news has you thinking about where robotics and automation could go next, it might be worth scanning our list of 30 robotics and automation stocks as a starting point for more ideas.

With Stryker trading at $387.02, sitting roughly 8% above one intrinsic estimate and around 10% below the average analyst target of $424.90, you have to ask: is there still a buying opportunity here, or is future growth already priced in?

Most Popular Narrative: 19.6% Overvalued

According to a widely followed narrative from user Tokyo, the fair value sits at $323.52 compared with Stryker's last close of $387.02, which puts the current price well above that estimate and frames the new robotics news against a richer starting point.

Investing in Stryker (SYK) should be an easy ride. Key “Take aways”:

• Solid balance sheet
• Earnings recovered, with positive outlook.
• SYK is fair priced.
• ROE over industry average (past and future)

Stryker has a solid balance sheet, I always want to see more equity than debt, which is the case with $19.2b (equity) versus $12.9b (debt) and leads to a debt to equity ratio of 67%. If we even take the cash position into account, which is $2.4b, the debt may be reduced to $10.5b, and we end up with a net debt to equity ratio of 54%.

Want to see how that balance sheet view supports a higher share price? Tokyo leans on growing free cash flow and rising returns on equity to justify that fair value. Curious which earnings and margin assumptions sit under the hood, and how far profitability is expected to stretch to make the numbers work?

Result: Fair Value of $323.52 (OVERVALUED)

However, that view could be challenged if free cash flow falls short of the US$5.0b target or if return on equity trends below the 21.9% expectation.

Next Steps

If this all sounds mixed to you, that is exactly why it helps to move quickly, review the data yourself, and weigh up the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Stryker has you thinking bigger picture, do not stop here. The right watchlist can come from casting a wider net across high quality opportunities.

• Target value potential by scanning 45 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their underlying strength.
• Strengthen your income stream by reviewing 13 dividend fortresses that focus on higher yielding companies aiming to keep payouts front and center.
• Sleep easier at night by checking 76 resilient stocks with low risk scores designed to spotlight businesses with more resilient profiles and lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.